IDH1 and acute myeloid leukemia: The topic of treatment-free remission has not yet been established in AML, particularly with IDH inhibitors, but considering the duration of this patient’s remission and deep molecular clearance demonstrated by MRD PCR-techniques and scMRD (NGS-based), we question whether it may be a possibility.